However, use of many CHK1 inhibitors has been terminated in clinical trials owing to their cellular or tissue toxicity or other side effects [48], which may be partially overcome by increasing the sensitivity of tumor cells to CHK1 inhibitors. This evidence concerns the gene CHEK1 and neoplasm.